MA53547A - Composés de 2,6-diamino pyridine - Google Patents

Composés de 2,6-diamino pyridine

Info

Publication number
MA53547A
MA53547A MA053547A MA53547A MA53547A MA 53547 A MA53547 A MA 53547A MA 053547 A MA053547 A MA 053547A MA 53547 A MA53547 A MA 53547A MA 53547 A MA53547 A MA 53547A
Authority
MA
Morocco
Prior art keywords
pyridine compounds
diamino pyridine
diamino
compounds
pyridine
Prior art date
Application number
MA053547A
Other languages
English (en)
Inventor
Timothy Barrett Durham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53547A publication Critical patent/MA53547A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053547A 2018-09-04 2019-08-29 Composés de 2,6-diamino pyridine MA53547A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726520P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
MA53547A true MA53547A (fr) 2022-04-27

Family

ID=67982138

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053547A MA53547A (fr) 2018-09-04 2019-08-29 Composés de 2,6-diamino pyridine

Country Status (28)

Country Link
US (1) US10781212B2 (fr)
EP (1) EP3846809B1 (fr)
JP (1) JP6813720B1 (fr)
KR (1) KR102365535B1 (fr)
CN (1) CN112601525B (fr)
AR (1) AR117640A1 (fr)
AU (1) AU2019334877B2 (fr)
BR (1) BR112021001881A2 (fr)
CA (1) CA3111725C (fr)
CL (1) CL2021000528A1 (fr)
CO (1) CO2021002768A2 (fr)
CR (1) CR20210085A (fr)
DO (1) DOP2021000027A (fr)
EA (1) EA202190302A1 (fr)
EC (1) ECSP21015267A (fr)
ES (1) ES2971802T3 (fr)
IL (1) IL280598B2 (fr)
JO (1) JOP20210039B1 (fr)
MA (1) MA53547A (fr)
MX (1) MX2021002472A (fr)
MY (1) MY200531A (fr)
PE (1) PE20211595A1 (fr)
PH (1) PH12021550449A1 (fr)
SG (1) SG11202101687TA (fr)
TW (1) TWI714231B (fr)
UA (1) UA124917C2 (fr)
WO (1) WO2020051058A1 (fr)
ZA (1) ZA202100700B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161621B2 (en) 2018-07-16 2024-12-10 The Regents Of The University Of Colorado Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
TWI750685B (zh) * 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
CN114846009B (zh) 2019-12-24 2023-12-12 杭州中美华东制药有限公司 具有khk抑制作用的化合物
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
JP2024501507A (ja) * 2020-12-25 2024-01-12 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド ケトヘキソキナーゼ阻害剤及びその用途
EP4681774A3 (fr) 2021-03-29 2026-03-25 Gilead Sciences, Inc. Inhibiteurs de la kinase de type kk
WO2023146785A1 (fr) * 2022-01-26 2023-08-03 Eli Lilly And Company Composés pyrrolidine
CN118679155A (zh) * 2022-02-09 2024-09-20 上海研健新药研发有限公司 一种khk抑制剂，其制备方法和应用
JP2025539698A (ja) * 2022-12-08 2025-12-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規シアノピリジンｋｈｋ阻害剤化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
AR099937A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MA40434B1 (fr) * 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze

Also Published As

Publication number Publication date
CN112601525A (zh) 2021-04-02
MY200531A (en) 2023-12-31
CN112601525B (zh) 2023-11-10
AR117640A1 (es) 2021-08-18
ZA202100700B (en) 2022-09-28
CL2021000528A1 (es) 2021-07-30
US10781212B2 (en) 2020-09-22
JOP20210039A1 (ar) 2021-03-04
JOP20210039B1 (ar) 2024-04-18
BR112021001881A2 (pt) 2021-04-27
EA202190302A1 (ru) 2021-06-10
NZ774406A (en) 2024-09-27
AU2019334877A1 (en) 2021-03-11
US20200071331A1 (en) 2020-03-05
WO2020051058A1 (fr) 2020-03-12
DOP2021000027A (es) 2021-03-15
IL280598B2 (en) 2024-02-01
SG11202101687TA (en) 2021-03-30
EP3846809B1 (fr) 2023-12-13
EP3846809A1 (fr) 2021-07-14
CO2021002768A2 (es) 2021-05-20
TWI714231B (zh) 2020-12-21
MX2021002472A (es) 2021-04-29
ECSP21015267A (es) 2021-04-29
IL280598A (en) 2021-03-25
CR20210085A (es) 2021-04-29
JP2021506949A (ja) 2021-02-22
AU2019334877B2 (en) 2022-07-28
JP6813720B1 (ja) 2021-01-13
IL280598B1 (en) 2023-10-01
PE20211595A1 (es) 2021-08-18
KR102365535B1 (ko) 2022-02-23
TW202026289A (zh) 2020-07-16
CA3111725C (fr) 2022-12-13
CA3111725A1 (fr) 2020-03-12
UA124917C2 (uk) 2021-12-08
PH12021550449A1 (en) 2021-09-27
ES2971802T3 (es) 2024-06-07
KR20210034082A (ko) 2021-03-29

Similar Documents

Publication Publication Date Title
MA53547A (fr) Composés de 2,6-diamino pyridine
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
EP3691623A4 (fr) Composés de benzosulfonyle
MA52560A (fr) Composés hétéroaryles tétracycliques
EP3802467A4 (fr) Composés spirocycliques
EP3720430A4 (fr) Composés benzocarbonyle
MA51669A (fr) Composés
EP3781156A4 (fr) Composés spirocycliques
EP4054724A4 (fr) Composés bifonctionnels
EP3746436A4 (fr) Composés cycliques condensés
MA53003A (fr) Composés
MA49701A (fr) Composés immunomodulateurs
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
MA44020A (fr) Composés antitumoraux
MA49639A (fr) Polymorphes de 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one
EP3853210A4 (fr) Composés antibactériens
MA50504A (fr) Composés antibactériens
EP3924358A4 (fr) Composés macrocycliques
EP3728289A4 (fr) Composés optimisés
MA52946A (fr) Composés
EP3464336A4 (fr) Composés
EP4077318A4 (fr) Composés
MA49621A (fr) Composés bifonctionnels